The EPS miss and JELMYTO guidance cut are the primary negatives, partially offset by ZUSDURI growth and UGN-103 NDA acceptance. Watch for UGN-103 PDUFA decision in June 2027 and any updates on the LONGVIEW-HR trial initiation.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 4 $28.74entry
- T+1 · 12d ago −10.47%α −6.06% · $25.73
- T+5 · 6d ago −9.19%α −8.27% · $26.10
- T+8 · todayOpen
- T+20 · in 16d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ZUSDURI revenue grew 35% QoQ to $68.0M, but JELMYTO revenue declined to $21.0M and full-year JELMYTO guidance was lowered to ~$90M from $97-101M. The FDA accepted the UGN-103 NDA with a PDUFA date of June 14, 2027.
Key Financial Metrics
Key Facts
- Total revenue $89.0M vs. $89.9M consensus (slight miss)
- ZUSDURI net product revenue $68.0M, up 35% QoQ
- JELMYTO net product revenue $21.0M, down from $25.7M YoY
- Full-year 2026 JELMYTO revenue guidance lowered to ~$90M from $97-101M
- FDA accepted UGN-103 NDA; PDUFA date June 14, 2027
- Net loss narrowed to $1.5M from $33.3M YoY
- Cash and equivalents $90.5M as of Sep 30, 2026
Financial Impact
EPS miss of $0.13 vs consensus; JELMYTO guidance cut by $7-11M; net loss improved by $31.8M YoY
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| ZUSDURI | $68.0M | +35.0% |
| JELMYTO | $21.0M | -18.3% |
Risk Factors
- JELMYTO revenue decline due to competitive trial enrollment and CMS adjustments
- UGN-103 approval uncertainty despite NDA acceptance
- Cash burn rate; $90.5M may require future financing
- Shareholders' deficit of $125M
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3395238 |
Track record
16 reports on URGN
4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +54.89% at T+60 after the Mar 2, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $25.90 Now $28.10 +8.49% settles Nov 23
- Nov 4, 202612d ago 8-K Neutral 5/10 No price data
- Nov 4, 202612d ago Press Release Bearish 6/10 Viewing Entry $28.74 to $26.10 Now $28.10 +2.23% ▲ +9.19% +8.27% vs SPY
- Nov 2, 202614d ago Press Release Neutral 4/10 Entry $34.36 to $26.31 Now $28.10 −18.22% ▼ −23.43% −23.51% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $33.75 to $28.74 Now $28.10 −16.74% ▼ −14.84% −14.13% vs SPY
- Oct 19, 202628d ago Press Release Bullish 6/10 Entry $34.15 to $34.23 Now $28.10 −17.72% ▲ +0.23% +0.38% vs SPY
- Oct 9, 20265w ago 144 Neutral 2/10 Entry $36.83 to $34.56 Now $28.10 −23.70% ▼ −6.16% −4.20% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 2/10 Entry $45.00 to $43.04 Now $28.10 −37.56% ▼ −4.36% −4.02% vs SPY
- Aug 20, 202612w ago 8-K Neutral 4/10 Entry $46.80 to $45.50 Now $28.10 −39.96% ▼ −2.78% −3.89% vs SPY
- Aug 5, 202614w ago 8-K Bullish 7/10 Entry $46.43 to $49.00 Now $28.10 −39.48% ▲ +5.54% +5.18% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers